Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. has announced the use of temporarily idle raised funds for cash management and the progress of its share repurchase plan, indicating a strategic approach to optimize financial resources and enhance shareholder value [1][3]. Group 1: Cash Management - The company and its subsidiaries have been authorized to use up to 700 million yuan of temporarily idle raised funds for cash management, investing in low-risk, high-liquidity principal-protected financial products [1]. - On July 3, 2025, the subsidiary Fujian Tongchun Pharmaceutical Co., Ltd. invested 40 million yuan in a structured deposit product from China Merchants Bank, which matured on July 31, 2025, yielding a return of 46,000 yuan [2]. - The principal and earnings from the structured deposit have been returned to the dedicated raised funds account, aligning with the company's cash management strategy [2]. Group 2: Share Repurchase - On March 14, 2025, the company approved a share repurchase plan with a total funding range of 70 million to 131.58 million yuan, with a maximum repurchase price of 7.31 yuan per share, to support the 2025 restricted stock incentive plan [3]. - As of July 31, 2025, the company has repurchased a total of approximately 16.30 million shares, representing 1.25% of the total share capital, with a total expenditure of approximately 80.26 million yuan [4]. - The repurchase activities are in compliance with relevant regulations and the company's established repurchase plan, with ongoing disclosures to keep investors informed [5].